乳腺癌新辅助治疗后豁免手术研究进展

doi:10.3969/j.issn.1009-976X.2025.04.010

摘要/Abstract

摘要： 在现代多学科治疗背景下,新辅助治疗（NAT）方案的改进显著提高了乳腺癌患者的病理学完全缓解率（pCR）。与存在残留病灶的患者相比,获得pCR的患者预后更佳。通过非手术方式准确识别pCR患者,可能使其豁免乳腺手术,但这一策略的成功依赖于诊断的准确性。早期乳腺癌患者新辅助治疗后通过真空辅助活检（VABB）评估肿瘤反应的准确性,以及根据活检评估结果豁免手术的安全性已有初步数据,但新辅助治疗后豁免乳腺手术尚有诸多问题尚待解决,仍需要进一步临床研究的验证。本综述旨在探讨新辅助治疗后pCR患者豁免乳腺手术的可行性。

关键词: 乳腺癌, 新辅助治疗, 豁免手术

Abstract: In the context of modern multidisciplinary therapy, the improvement of neoadjuvant therapy （NAT） has increased the pathologic complete response （pCR） rate in breast cancer patients. Compared to patients with residual disease, those achieving pCR demonstrate superior prognosis. Accurate non-surgical identification of pCR patients may allow for the omission of breast surgery, but the success of this strategy hinges on diagnostic precision. Preliminary data exist regarding the accuracy of vacuum-assisted breast biopsy （VABB） for assessing tumor response after neoadjuvant therapy in early-stage breast cancer, as well as the feasibility of omitting surgery based on biopsy findings. However, several unresolved issues remain regarding breast surgery omission after NAT, and further clinical trial validation is needed. This review aims to explore the feasibility of omitting breastsurgery in patients who achieve pCR after neoadjuvant therapy.

Key words: breast cancer, neoadjuvant therapy, omission of surgery

中图分类号:

R737.9

严孟欣, 陈翔. 乳腺癌新辅助治疗后豁免手术研究进展[J]. 岭南现代临床外科, 2025, 25(04): 273-280.

YAN Meng-xin, CHEN Xiang. Research progress on surgical omission after neoadjuvant therapy for breast cancer[J]. Lingnan Modern Clinics In Surgery, 2025, 25(04): 273-280.

参考文献

[1] Korde LA, Somerfield MR, Carey LA, et al.Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline[J]. J Clin Oncol, 2021, 39(13): 1485-1505.
[2] 《中国乳腺癌新辅助治疗专家共识(2022年版)》专家组. 中国乳腺癌新辅助治疗专家共识(2022年版)[J]. 中国癌症杂志, 2022, 32(1): 80-89.
[3] Simons JM, Jacobs JG, Roijers JP, et al.Disease-free and overall survival after neoadjuvant chemotherapy in breast cancer: breast-conserving surgery compared to mastectomy in a large single-centre cohort study[J]. Breast Cancer Res Treat, 2021, 185(2): 441-451.
[4] Montagna G, Mrdutt MM, Sun SX, et al.Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy[J]. JAMA Oncol, 2024, 10(6): 793-798.
[5] Conforti F, Pala L, Sala I, et al.Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis[J]. BMJ, 2021, 375: e066381.
[6] Lee JS, Yost SE, Yuan Y.Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges[J]. Cancers (Basel), 2020, 12(6): 1404.
[7] Schmid P, Cortes J, Pusztai L, et al.Pembrolizumab for Early Triple-Negative Breast Cancer[J]. N Engl J Med, 2020, 382(9): 810-821.
[8] Connors C, Valente SA, Elsherif A, et al.Real-World Outcomes with the KEYNOTE-522 Regimen in Early-Stage Triple-Negative Breast Cancer[J]. Ann Surg Oncol, 2025, 32(2): 912-921.
[9] Levee A, Wong M, Flores S, et al.Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: a real-world analysis[J]. Oncologist, 2024, 29(7): 566-574.
[10] Heil J, Kümmel S, Schaefgen B, et al.Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques[J]. Br J Cancer, 2015, 113(11): 1565-1570.
[11] Kuerer HM, Rauch GM, Krishnamurthy S, et al.A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy[J]. Ann Surg, 2018, 267(5): 946-951.
[12] Shen A, Qiang W, Zhao H, et al.Contemporaneous Symptom Networks of Breast Cancer-Related Upper Limb Lymphedema: A Network Analysis[J]. Ann Surg Oncol, 2024, 31(10): 6611-6622.
[13] Al-Hilli Z, Wilkerson A.Breast Surgery: Management of Postoperative Complications Following Operations for Breast Cancer[J]. Surg Clin North Am, 2021, 101(5): 845-863.
[14] Parra RFDVL, Kuerer HM.Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials[J]. Breast Cancer Res, 2016, 18(1): 28.
[15] Touboul E, Buffat L, Lefranc JP, et al.Possibility of conservative local treatment after combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer[J]. Int J Radiat Oncol Biol Phys, 1996, 34(5): 1019-1028.
[16] Ring A, Webb A, Ashley S, et al.Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer[J]. J Clin Oncol, 2003, 21(24): 4540-4545.
[17] Daveau C, Savignoni A, Abrous-Anane S, et al.Is radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy[J]. Int J Radiat Oncol Biol Phys, 2011, 79(5): 1452-1459.
[18] Özkurt E, Sakai T, Wong SM, et al.Survival Outcomes for Patients With Clinical Complete Response After Neoadjuvant Chemotherapy: Is Omitting Surgery an Option[J]. Ann Surg Oncol, 2019, 26(10): 3260-3268.
[19] Gentile D, Sagona A, Carlo CD, et al.Pathologic response and residual tumor cellularity after neo-adjuvant chemotherapy predict prognosis in breast cancer patients[J]. Breast, 2023, 69: 323-329.
[20] Broglio KR, Quintana M, Foster M, et al.Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2- Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis[J]. JAMA Oncol, 2016, 2(6): 751-760.
[21] Cortazar P, Zhang L, Untch M, et al.Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis[J]. Lancet, 2014, 384(9938): 164-172.
[22] Petrelli F, Tomasello G, Parati MC, et al.Different Chemotherapy Regimens and Pathologic Complete Response in Triple-Negative Breast Cancer: An Updated Network Meta-Analysis of Phase 3 Trials[J]. Medicina (Kaunas), 2024, 60(2): 341.
[23] Liu Y, Fan L, Wang Z, et al.Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase Ⅱ Study[J]. Oncologist, 2023, 28(1): 86-e76.
[24] Swain SM, Ewer MS, Viale G, et al.Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study[J]. Ann Oncol, 2018, 29(3): 646-653.
[25] Hurvitz SA, Martin M, Symmans WF, et al.Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet Oncol, 2018, 19(1): 115-126.
[26] Huang L, Pang D, Yang H, et al.Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial[J]. Nat Commun, 2024, 15(1): 2153.
[27] Shao Z, Pang D, Yang H, et al.Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial[J]. JAMA Oncol, 2020, 6(3): e193692.
[28] Kuehn T, Bauerfeind I, Fehm T, et al.Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study[J]. Lancet Oncol, 2013, 14(7): 609-618.
[29] Boughey JC, Suman VJ, Mittendorf EA, et al.Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial[J]. JAMA, 2013, 310(14): 1455-1461.
[30] Caudle AS, Yang WT, Krishnamurthy S, et al.Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection[J]. J Clin Oncol, 2016, 34(10): 1072-1078.
[31] Kuemmel S, Heil J, Bruzas S, et al.Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast Cancer[J]. JAMA Surg, 2023, 158(8): 807-815.
[32] Barron AU, Hoskin TL, Day CN, et al.Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy[J]. JAMA Surg, 2018, 153(12): 1120-1126.
[33] Samiei S, Nijnatten TJAV, Munck LD, et al.Correlation Between Pathologic Complete Response in the Breast and Absence of Axillary Lymph Node Metastases After Neoadjuvant Systemic Therapy[J]. Ann Surg, 2020, 271(3): 574-580.
[34] Tadros AB, Yang WT, Krishnamurthy S, et al.Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery[J]. JAMA Surg, 2017, 152(7): 665-670.
[35] Heil J, Sinn P, Richter H, et al.RESPONDER - diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial[J]. BMC Cancer, 2018, 18(1): 851.
[36] Krag DN, Anderson SJ, Julian TB, et al.Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial[J]. Lancet Oncol, 2010, 11(10): 927-933.
[37] Chagpar AB, Middleton LP, Sahin AA, et al.Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy[J]. Ann Surg, 2006, 243(2): 257-264.
[38] Baumgartner A, Tausch C, Hosch S, et al.Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients[J]. Breast, 2018, 39: 19-23.
[39] Schaefgen B, Mati M, Sinn HP, et al.Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response[J]. Ann Surg Oncol, 2016, 23(3): 789-795.
[40] Janssen LM, Dekker BMD, Gilhuijs KGA, et al.MRI to assess response after neoadjuvant chemotherapy in breast cancer subtypes: a systematic review and meta-analysis[J]. NPJ Breast Cancer, 2022, 8(1): 107.
[41] Reis J, Lindstrøm JC, Boavida J, et al.Accuracy of breast MRI in patients receiving neoadjuvant endocrine therapy: comprehensive imaging analysis and correlation with clinical and pathological assessments[J]. Breast Cancer Res Treat, 2020, 184(2): 407-420.
[42] Gebhart G, Keyaerts M, Guiot T, et al.Optimal[18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial[J]. J Nucl Med, 2024, 65(5): 708-713.
[43] Ghanikolahloo M, Taher HJ, Abdullah AD, et al.The role of 18F-FDG PET/MRI in assessing pathological complete response to neoadjuvant chemotherapy in patients with breast cancer: a systematic review and meta-analysis[J]. Radiat Oncol, 2024, 19(1): 164.
[44] Chen L, Zheng S, Chen L, et al.68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study[J]. J Nucl Med, 2023, 64(12): 1899-1905.
[45] Heil J, Schaefgen B, Sinn P, et al.Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy[J]. Eur J Cancer, 2016, 69: 142-150.
[46] Loevezijn AAV, Noordaa MEMVD, Werkhoven EDV, et al.Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study[J]. Ann Surg Oncol, 2021, 28(6): 3243-3253.
[47] Tasoulis MK, Lee H, Yang W, et al.Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer[J]. JAMA Surg, 2020, 155(12): e204103.
[48] Lee H, Han W, Kim S, et al.Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial[J]. Breast Cancer Res Treat, 2020, 182(1): 97-105.
[49] Koelbel V, Pfob A, Schaefgen B, et al.Vacuum-Assisted Breast Biopsy After Neoadjuvant Systemic Treatment for Reliable Exclusion of Residual Cancer in Breast Cancer Patients[J]. Ann Surg Oncol, 2022, 29(2): 1076-1084.
[50] Pfob A, Sidey-Gibbons C, Lee H, et al.Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy[J]. Eur J Cancer, 2021, 143: 134-146.
[51] Jung J, Cheun J, Kim S, et al.Omission of Breast Surgery in Predicted Pathologic Complete Response after Neoadjuvant Systemic Therapy: A Multicenter, Single-Arm, Non-inferiority Trial[J]. J Breast Cancer, 2024, 27(1): 61-71.
[52] Neoadjuvant chemotherapy combined with neoadjuvant radiotherapy in breast cancer - Clinical Trials Registry - ICH GCP[EB/OL].[2025-07-14].https://ichgcp.net/clinical-trials-registry/NCT06498154.
[53] TAUSCH P D med C. Intelligent vacuum assisted biopsy immediately before surgery as an intra- or pre-operative surrogate for patient response to neoadjuvant chemotherapy for breast cancer (VISION I): A multicenter prospective feasibility trial: NCT04289935[R/OL]. clinicaltrials.gov, 2024.[2025-07-14]. https://clinicaltrials.gov/study/NCT04289935.
[54] Ku GDLC, Karamchandani M, Chambergo-Michilot D, et al.Does Breast-Conserving Surgery with Radiotherapy have a Better Survival than Mastectomy? A Meta-Analysis of More than 1,500,000 Patients[J]. Ann Surg Oncol, 2022, 29(10): 6163-6188.